104 related articles for article (PubMed ID: 22388607)
1. Low prevalence of high-dose methotrexate nephropathy in patients with malignancy.
Mashhadi MA; Kaykhaei MA; Sanadgol H
Iran J Kidney Dis; 2012 Mar; 6(2):105-9. PubMed ID: 22388607
[TBL] [Abstract][Full Text] [Related]
2. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
3. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
5. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide nephropathy in patients with sarcoma.
Mashhadi MA; Sanadgol H; Keikhaei M
Iran J Kidney Dis; 2011 Jul; 5(4):238-41. PubMed ID: 21725180
[TBL] [Abstract][Full Text] [Related]
8. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
Cwliklińska M; Balwierz W; Nowak J; Stanuch H
Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
[TBL] [Abstract][Full Text] [Related]
12. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
13. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
15. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of renal function in Turkish children receiving BFM-95 therapy for acute lymphoblastic leukemia.
Kaya Z; Gursel T; Bakkaloglu SA; Kocak U; Atasever T; Oktar SO
Pediatr Hematol Oncol; 2007 Jun; 24(4):257-67. PubMed ID: 17613868
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
18. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
19. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
20. Severe methotrexate toxicity precipitated by intravenous radiographic contrast.
Harned TM; Mascarenhas L
J Pediatr Hematol Oncol; 2007 Jul; 29(7):496-9. PubMed ID: 17609630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
